Overview / Abstract: |
Faculty Gary Sachs, MD Michael E. Thase, MD Intended Learners Learning Objectives Differentially diagnose depressive mental illnesses, focusing on new DSM-5 specifiers and various patient presentations along the disease continuum CME CNE Nursing Pharmacology Credits APA Method of Participation There is no fee associated with this activity. For questions regarding this educational activity, please call 609-371-1137. Independent Clinical Reviewer: William C. Torrey, MD, Professor of Psychiatry, Vice Chair for Clinical Services, Department of Psychiatry, Grisel School of Medicine at Dartmouth, Lebanon, New Hampshire Nurse Planner: Andrew Penn, RN, MS, NP, CNS, APRN-BC, Psychiatric Nurse Practitioner,Kaiser Permanente, Redwood City, California; Assistant Clinical Professor, University of California, San Francisco, California Planning Committee Financial Disclosure and Conflicts of Interest Dr. Calabrese is a consultant to Dainippon Sumitomo Pharma Co.; Ltd, Forest Laboratories, Inc.; GlaxoSmithKline plc; Janssen Pharmaceuticals, Inc.; Medscape; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd. Dr. Sachs is the owner and part-time employee of Collaborative Care Initiative and full-time employee of Bracket. Dr. Sachs is a consultant and advisory board member for Sunovion Pharmaceuticals Inc. and Takeda Pharmaceutical Company Ltd. Dr. Sachs is a shareholder of athenahealth, Inc. and Express Scripts. Dr. Thase receives grant/research support from the Agency for Healthcare Research and Quality; Alkermes plc; AssureRx; Avanir Pharmaceuticals, Inc.; Forest Laboratoriess, Inc., Janssen Pharmaceuticals, Inc ., National Institute of Mental Health (NIMH), Otsuka Pharmaceutical Co., Ltd. Dr. Thase is an adviser/consultant forAlkermes; Allergan; AstraZeneca; Bristol-Myers Squibb Company; Cerecor Inc.; Eli Lilly and Company; Fabre-Kramer Pharmaceuticals, Inc.; Forest Laboratories, Inc.; Gerson Lehrman Group, Inc.; GlaxoSmithKline plc; Guidepoint Global, LLC; H. Lundbeck A/S, MedAvante, Inc.; Merck & Co., Inc. (formerly Schering Plough and Organon); moksha8 Pharmaceuticals Inc.; Naurex Inc., Neuronetics, Inc.; Novartis AG; Ortho-McNeil Pharmaceuticals (Johnson & Johnson; Janssen); Otsuka Pharmaceutical Co., Ltd.; Pamlab, Inc. (Nestle); Pfizer Inc.; Shire US Inc; Sunovion Pharmaceuticals Inc.; Trius Therapeutics, Inc.;Takeda Pharmaceutical Company Ltd. He has equity holdings in MedAvante, Inc; royalties from American Psychiatric Foundation, Guildford Publications, Inc.; Herald Publishing House, and W.W. Norton & Company, Inc; and Spouse’s Employment is with Peloton Advantage, LLC. Mr. Penn and Dr. Torrey disclosed no relevant financial relationships with any commercial interests. Ms. Gaerlan, Mr. Kearney, Ms. O’Brien, Mr. Robbin, Mr. Savage; Dr. O’Connor disclosed no relevant financial relationships with any commercial interests. NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations. The off-label or investigational use of Lurasidone and Lamotrigine for the treatment of depression with mixed features will be discussed. Privacy Policy NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information. |
Expiration |
Dec 30, 2016 |
Discipline(s) |
Nurse Practitioner , Physician CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.00 |
Accreditation |
NACCME |
Presenters / Authors / Faculty |
Faculty Gary Sachs, MD Michael E. Thase, MD |
Activity Specialities / Related Topics |
Depression / Bipolar, Primary Care, Psychiatry / Mental Health |
Sponsors / Supporters / Grant Providers |
Jointly provided by North American Center for Continuing Medical Education, LLC, an HMP Communications Holdings Company, and Integritas Communications. |
Keywords / Search Terms |
Integritas Communications Depression, Bipolar, Mental Illnesses Free CE CME |